DiaMedica Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DMAC Nasdaq 2836 www.diamedica.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - May 12th, 2026 2:15 pm
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans - May 10th, 2026 8:59 am
DiaMedica Therapeutics Q1 Earnings Call Highlights - May 7th, 2026 11:42 am
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - May 6th, 2026 2:30 pm
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - Apr 30th, 2026 6:25 am
RedChip's Biotech Virtual Investor Conference Replays Now Available - Apr 21st, 2026 1:00 pm
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference - Apr 16th, 2026 10:04 am
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Apr 7th, 2026 9:00 am
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... - Mar 31st, 2026 1:01 pm
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary - Mar 31st, 2026 10:40 am
DiaMedica Therapeutics Q4 Earnings Call Highlights - Mar 31st, 2026 7:26 am
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Mar 30th, 2026 2:45 pm
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - Mar 23rd, 2026 6:25 am
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Mar 5th, 2026 5:35 am
Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Mar 2nd, 2026 11:00 am
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Feb 24th, 2026 7:23 am
DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings - Feb 15th, 2026 5:36 am
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 16th, 2026 3:00 pm
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Dec 18th, 2025 6:45 am
Huge Insider Buying in MGM and Salesforce - Dec 12th, 2025 7:45 am